Sirolimus-eluting coronary stent - Micell Technologies

Drug Profile

Sirolimus-eluting coronary stent - Micell Technologies

Alternative Names: MiStent; MiStent SES

Latest Information Update: 14 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Micell Technologies
  • Developer Micell Technologies; Stentys
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • Phase III Coronary disorders

Most Recent Events

  • 01 Aug 2016 Micell Technologies completes the DESSOLVE II phase II trial for Coronary artery restenosis prevention in Belgium, France, the Netherlands, Sweden, United Kingdom and New Zealand (NCT01294748)
  • 22 Mar 2016 Micell completes enrolment in MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT) study trial for Coronary artery restenosis in USA
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top